Stomach cancer classification: Difference between revisions
(Replaced content with "__NOTOC__ {{CMG}}{{AE}}{{PSD}} {{Stomach cancer}} ==Overview== ==Classification== ==References== {{Reflist|2}} {{WH}} {{WS}}") |
|||
(13 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}{{AE}}{{PSD}} | {{CMG}};{{AE}} {{OK}}, {{PSD}}, {{MAD}} | ||
{{Stomach cancer}} | {{Stomach cancer}} | ||
==Overview== | ==Overview== | ||
[[Gastric cancer]] can be classified according to the Padova [[classification]] [[system]] based upon the grade of [[metaplasia]], [[dysplasia]] and invasiveness of the [[disease]]. It may also be classified according to the Japanese classification system based on the type of [[lesions]] ([[benign]] or [[malignant]]) and [[atypia]]. | |||
==Classification== | ==Classification== | ||
[[Gastric cancer]] can be classified according to the Padova [[classification]] [[system]] based upon the grade of [[metaplasia]], [[dysplasia]] and invasiveness of the [[disease]]. It may also be classified according to the Japanese classification system based on the type of [[lesions]] ([[benign]] or [[malignant]]) and [[atypia]]. The following tables briefly outline the major [[classification]] [[systems]]:<ref name="pmid10680883">{{cite journal| author=Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K et al.| title=Gastric dysplasia: the Padova international classification. | journal=Am J Surg Pathol | year= 2000 | volume= 24 | issue= 2 | pages= 167-76 | pmid=10680883 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10680883 }}</ref><ref name="pmid27342689">{{cite journal| author=Japanese Gastric Cancer Association| title=Japanese gastric cancer treatment guidelines 2014 (ver. 4). | journal=Gastric Cancer | year= 2017 | volume= 20 | issue= 1 | pages= 1-19 | pmid=27342689 | doi=10.1007/s10120-016-0622-4 | pmc=5215069 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27342689 }}</ref> | |||
=== '''Padova classification''' === | |||
{| class="wikitable" | |||
! colspan="2" |'''1. Negative for [[dysplasia]]''' | |||
|- | |||
!1.0 | |||
|Normal | |||
|- | |||
!1.1 | |||
|Reactive foveolar [[hyperplasia]] | |||
|- | |||
!1.2 | |||
|Intestinal [[metaplasia]] (IM) | |||
|- | |||
!1.2.1 | |||
|IM Complete type | |||
|- | |||
!1.2.2 | |||
|IM Incomplete type | |||
|- | |||
! colspan="2" |'''2. Indefinite for [[dysplasia]]''' | |||
|- | |||
!2.1 | |||
|Foveolar hyperproliferation | |||
|- | |||
!2.2 | |||
|Hyperproliferative IM | |||
|- | |||
| colspan="2" |'''3. Non-invasive [[neoplasia]] (flat or elevated [synonym adenoma])''' | |||
|- | |||
!3.1 | |||
|Low-grade | |||
|- | |||
!3.2 | |||
|High-grade | |||
|- | |||
!3.2.1 | |||
|Including suspicious for [[carcinoma]] without [[invasion]] (interglandular) | |||
|- | |||
!3.2.2 | |||
|Including [[carcinoma]] without invasion (intraglandular) | |||
|- | |||
! colspan="2" |'''4. Suspicious for invasive [[carcinoma]]''' | |||
|- | |||
! colspan="2" |'''5. Invasive [[adenocarcinoma]]''' | |||
|} | |||
=== Japanese classification === | |||
{| class="wikitable" | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Category | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Definition | |||
|- | |||
!Group I | |||
|Normal [[mucosa]] and [[benign]] [[lesions]] with no [[atypia]] | |||
|- | |||
!Group II | |||
|[[Lesions]] showing [[atypia]] but diagnosed as [[benign]] (non-[[Neoplastic disease|neoplastic]]) | |||
|- | |||
!Group III | |||
|Borderline [[lesions]] between [[benign]] and [[malignant]] | |||
|- | |||
!Group V | |||
|[[Lesions]] strongly suspected of [[carcinoma]] | |||
|- | |||
!Group V | |||
|[[Carcinoma]] | |||
|} | |||
==References== | ==References== |
Latest revision as of 23:04, 4 April 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2], Parminder Dhingra, M.D. [3], Mohammed Abdelwahed M.D[4]
Stomach cancer Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Stomach cancer classification On the Web |
American Roentgen Ray Society Images of Stomach cancer classification |
Risk calculators and risk factors for Stomach cancer classification |
Overview
Gastric cancer can be classified according to the Padova classification system based upon the grade of metaplasia, dysplasia and invasiveness of the disease. It may also be classified according to the Japanese classification system based on the type of lesions (benign or malignant) and atypia.
Classification
Gastric cancer can be classified according to the Padova classification system based upon the grade of metaplasia, dysplasia and invasiveness of the disease. It may also be classified according to the Japanese classification system based on the type of lesions (benign or malignant) and atypia. The following tables briefly outline the major classification systems:[1][2]
Padova classification
1. Negative for dysplasia | |
---|---|
1.0 | Normal |
1.1 | Reactive foveolar hyperplasia |
1.2 | Intestinal metaplasia (IM) |
1.2.1 | IM Complete type |
1.2.2 | IM Incomplete type |
2. Indefinite for dysplasia | |
2.1 | Foveolar hyperproliferation |
2.2 | Hyperproliferative IM |
3. Non-invasive neoplasia (flat or elevated [synonym adenoma]) | |
3.1 | Low-grade |
3.2 | High-grade |
3.2.1 | Including suspicious for carcinoma without invasion (interglandular) |
3.2.2 | Including carcinoma without invasion (intraglandular) |
4. Suspicious for invasive carcinoma | |
5. Invasive adenocarcinoma |
Japanese classification
Category | Definition |
---|---|
Group I | Normal mucosa and benign lesions with no atypia |
Group II | Lesions showing atypia but diagnosed as benign (non-neoplastic) |
Group III | Borderline lesions between benign and malignant |
Group V | Lesions strongly suspected of carcinoma |
Group V | Carcinoma |
References
- ↑ Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K; et al. (2000). "Gastric dysplasia: the Padova international classification". Am J Surg Pathol. 24 (2): 167–76. PMID 10680883.
- ↑ Japanese Gastric Cancer Association (2017). "Japanese gastric cancer treatment guidelines 2014 (ver. 4)". Gastric Cancer. 20 (1): 1–19. doi:10.1007/s10120-016-0622-4. PMC 5215069. PMID 27342689.